ProCE Banner Activity

Podcast Pearls
Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations

PDF
Podcast Episodes
Download this PDF resource with summary points from a podcast episode featuring Sara Tinsley, PhD, APRN, AOCN, discussing the use of targeted therapies in patients with FLT3 or IDH1/2 mutated AML

Released: January 06, 2022

Expiration: January 05, 2023

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AbbVie

Faculty Disclosure

Primary Author

Sara Tinsley-Vance, PhD, MSN, APRN-BC, AOCN

Nurse Practitioner and Researcher
Malignant Hematology
Moffitt Cancer Center
Tampa, Florida

Sara M. Tinsley, PhD, APRN, AOCN, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb, Incyte, and Taiho and fees for non-CME services from Astellas, Bristol-Myers Squibb, and Incyte.